Over the past decade, South Africa's market for hormones in dosage, excluding contraceptives and antibiotics, has experienced a gradual decline in value per capita from $3.58 in 2013 to a modest $2.65 in 2023. Notably, the year-on-year variation from 2022 to 2023 was a decrease of 2.22%, and from 2021 to 2022, it was a decline of 6.55%. Over the last five years, from 2018 to 2023, the compound annual growth rate (CAGR) showed a steady decrease of approximately 2.04% per year.

Future trends to watch for include:

Increasing advancements in biotechnology which could alter market dynamics.
Potential policy changes affecting healthcare funding and pharmacological pricing.
Demand shifts driven by demographic changes and chronic disease prevalence.